耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay)
TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase
(注:單次混測多因子不超過8個指標(biāo) )
- 編號LMA902Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.02-20ng/mL
- 靈敏度最小可檢測劑量小于等于0.007 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 計(jì)算器 ¥ 4536 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計(jì)算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 97-105 | 101 |
EDTA plasma(n=5) | 94-103 | 97 |
heparin plasma(n=5) | 82-94 | 89 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 97-105% | 85-94% | 79-93% | 98-105% |
EDTA plasma(n=5) | 79-96% | 80-101% | 78-102% | 87-101% |
heparin plasma(n=5) | 94-101% | 78-102% | 84-105% | 89-98% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA902Hu01 | 耐酒石酸酸性磷酸酶(ACP5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA902Hu01 | 耐酒石酸酸性磷酸酶(ACP5)多克隆抗體 | WB; IHC; ICC; IP. |
MAA902Hu22 | 耐酒石酸酸性磷酸酶(ACP5)單克隆抗體 | WB; IHC; ICC; IP. |
SEA902Hu | 耐酒石酸酸性磷酸酶(ACP5)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA902Hu | 耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Archives of Oral Biology | Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats [ScienceDirect: S0003996912001021] |
Life Sciences | Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes [PubMed: 23357248] |
International Journal of Cardiology | Valvular osteoclasts in calcification and aortic valve stenosis severity. [Pubmed: 23452891] |
Evidence-Based Complementary and Alternative Medicine | Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice [Pubmed:25737735] |
Advances in Medical Sciences | The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats [PubMed: 26569440] |
Bone | The effects of strength training and raloxifene on bone health in aging ovariectomized rats [Pubmed:26812611] |
Journal of Clinical Medicine Research | In?Vitro?and In?Vivo?Effects?of?Gracilaria?verrucosa?Extracts?on?Osteoclast?Differentiation. [pubmed:28335442] |
Biomedicine & Pharmacotherapy | Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats [S0753332216322752] |
Clinical Trials in Degenerative Diseases | Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial [issn:2542-3975] |
Scientific Reports | Evidence for excessive osteoclast activation in SIRT6 null mice [Pubmed:30030453] |
International?Journal?of?Molecular?Sciences? | Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo [Pubmed:29562730] |
Experimental Gerontology | The decline of whole-body glucose metabolism in ovariectomized rats [Pubmed: 30292771] |
Bone?Research | NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts [Pubmed: 30455992] |
Cell Death & Disease | QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism [Pubmed: 32382069] |
Effect of Corticopuncture (CP), Photobiomodulation (PBM) and the Combined Method on the Rate of Tooth Movement and Root Resorption: A Molecular, Histological … [] | |
Evid Based Complement Alternat Med | Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway [34512780] |